Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial

Trial Profile

Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Retinopathy of prematurity
  • Focus Therapeutic Use
  • Acronyms BEAT-ROP
  • Most Recent Events

    • 21 Feb 2016 Planned End Date changed from 1 Oct 2017 to 1 Aug 2020 as per ClinicalTrials.gov record.
    • 18 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top